期刊
CLINICA CHIMICA ACTA
卷 414, 期 -, 页码 171-178出版社
ELSEVIER
DOI: 10.1016/j.cca.2012.08.013
关键词
Alzheimer's disease; APP; BACE1; Amyloid-beta peptide; X-ray crystal structure of BACE1; Inhibitors of BACE1
资金
- Department of Biotechnology (DBT), Ministry of Science and Technology, Govt. of India
- Bharathidasan University
Targeting BACE1 (beta-site APP cleaving enzyme 1 or beta-secretase) is the focus of Alzheimer's disease (AD) research because this aspartyl protease is involved in the abnormal production of beta amyloid plaques (A beta), the hallmark of its pathophysiology. Evidence suggests that there is a strong connection between AD and BACE1. As such, strategies to inhibit A beta formation in the brain should prove beneficial for AD treatment. A beta, the product of the large type1 trans-membrane protein amyloid precursor protein (APP), is produced in a two-step proteolytic process initiated by BACE1 (beta-secretase) and followed by gamma-secretase. Due to its apparent rate limiting function, BACE1 appears to be a prime target to prevent A beta generation in AD. Following its discovery, the BACE1 has been cloned, its structure solved, novel physiologic substrates discovered and numerous inhibitors developed. This review focuses on elucidating the role of BACE1 to facilitate drug development in the treatment of AD. (C) 2012 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据